Cancer patients who respond to avelumab can keep taking it in this Follow-Up study
NCT ID NCT05059522
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study offers continued access to the cancer drug avelumab (and sometimes other drugs) for people with advanced cancers like lung, ovarian, or bladder cancer who are already seeing benefits from a previous Pfizer-sponsored trial. About 77 participants will be followed for safety and survival. The goal is not to test new effectiveness, but to allow ongoing treatment and monitor side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
avelumab (with possible combinations: lorlatinib, talazoparib, pemetrexed, axitinib, CMP 001, utomilumab, PF04518600)
What this could lead to
If successful, this study allows patients who are already benefiting from avelumab to keep receiving it, potentially extending their disease control.
What could go wrong
This is an open-label continuation study, not a new treatment test. It does not prove the drug works for new patients, and side effects may still occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aalborg Universitetshospital, Syd
Aalborg, North Denmark, 9000, Denmark
-
Asan Medical Center
Seoul, Seoul-teukbyeolsi [seoul], 05505, South Korea
-
Auckland City Hospital
Auckland, 1023, New Zealand
-
Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi
Ancona, 60126, Italy
-
Budgetary Healthcare Institution of Omsk Region "Clinical Oncology Dispensary"
Omsk, Omsk Oblast, 644013, Russia
-
Centralny Szpital Kliniczny MSWiA w Warszawie
Warsaw, 02-507, Poland
-
Chang Gung Medical Foundation-Linkou Branch
Taoyuan, 333, Taiwan
-
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
-
FBIH "Privolzhskiy Regional Medical Center" of FMBA
Nizhny Novgorod, 603109, Russia
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Lombardy, 20133, Italy
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Milano, 20133, Italy
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
GBUZ SK Pyatigorsk Interdistrict Oncology dispensary
Pyatigorsk, Stavropol Kray, 357502, Russia
-
Gachon University Gil Medical Center
Namdong-gu, Incheon-gwangyeoksi [incheon], 21565, South Korea
-
Grand Hôpital de Charleroi
Gilly, 6060, Belgium
-
Highlands Oncology Group, PA
Fayetteville, Arkansas, 72703, United States
-
Highlands Oncology Group, PA
Rogers, Arkansas, 72758, United States
-
Highlands Oncology Group, PA
Springdale, Arkansas, 72762, United States
-
Hospital Clínic de Barcelona
Barcelona, Barcelona [barcelona], 08036, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona [barcelona], 08035, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
Monterrey, Nuevo León, 64460, Mexico
-
Hospital Universitario Fundación Jiménez Díaz
Madrid, 28040, Spain
-
Hospital Universitario HM Sanchinarro
Madrid, 28050, Spain
-
Hospital Universitario Virgen de Valme
Seville, 41014, Spain
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
IRCCS Istituto Clinico Humanitas
Rozzano, Milano, 20089, Italy
-
Institut Català d'Oncologia - L'Hospitalet
L'Hospitalet de Llobregat, Barcelona, 08908, Spain
-
Institut de Cancérologie de Lorraine Alexis Vautrin
Vandœuvre-lès-Nancy, Lorraine, 54519, France
-
Institute for Oncology and Radiology of Serbia
Belgrade, 11000, Serbia
-
Japanese Foundation for Cancer Research
Koto, Tokyo, 135-8550, Japan
-
Kingston Health Sciences Centre-Kingston General Hospital Site
Kingston, Ontario, K7L 2V7, Canada
-
MSK Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
MSK Bergen
Montvale, New Jersey, 07645, United States
-
MSK Commack
Commack, New York, 11725, United States
-
MSK Monmouth
Middletown, New Jersey, 07748, United States
-
MSK Nassau
Uniondale, New York, 11553, United States
-
MSK Westchester
Harrison, New York, 10604, United States
-
Macquarie University
North Ryde, New South Wales, 2109, Australia
-
Mater Hospital Sydney
Wollstonecraft, New South Wales, 2060, Australia
-
Melanoma Institute Australia
Wollstonecraft, New South Wales, 2065, Australia
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center (IDS Pharmacy)
Long Island City, New York, 11101, United States
-
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
New York, New York, 10021, United States
-
Memorial Sloan Kettering Cancer Center 53rd street.
New York, New York, 10022, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Moscow Scientific Research Oncology Institute n.a. P.A. Hertzen
Moscow, 125284, Russia
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
Warsaw, 02-781, Poland
-
National Cancer Center
Goyang-si, Kyǒnggi-do, 10408, South Korea
-
National Cancer Center Hospital
Chuo-ku, Tokyo, 104-0045, Japan
-
National Cheng Kung University Hospital
Tainan, 704, Taiwan
-
National Hospital Organization Kyushu Cancer Center
Fukuoka, 811-1395, Japan
-
National Taiwan University Hospital
Taipei, 10002, Taiwan
-
Oaxaca Site Management Organization S.C.
Oaxaca City, 68000, Mexico
-
Oita University Hospital
Yufu, Oita Prefecture, 879-5593, Japan
-
Országos Onkológiai Intézet
Budapest, 1122, Hungary
-
Private Medical Institution "Euromedservice"
Pushkin, Sankt-Peterburg, 196603, Russia
-
Rabin Medical Center
Petah Tikva, Central District, 4941492, Israel
-
Royal Cornwall Hospitals NHS Trust
Truro, TR1 3LJ, United Kingdom
-
Royal Marsden NHS Foundation Trust
London, SW3 6JJ, United Kingdom
-
SAHI Republican Clinical Oncology Dispensary under the Ministry of Health, Republic of Bashkortostan
Ufa, 450054, Russia
-
Samsung Medical Center
Seoul, Seoul-teukbyeolsi [seoul], 06351, South Korea
-
Seoul National University Bundang Hospital
Seongnam, Kyǒnggi-do, 13620, South Korea
-
Seoul National University Hospital
Seoul, Seoul-teukbyeolsi [seoul], 03080, South Korea
-
The Newcastle Upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, NE7 7DN, United Kingdom
-
The Prince Charles Hospital
Chermside, Queensland, 4032, Australia
-
The Regents of the University of California
Los Angeles, California, 900095, United States
-
The Trustees of the University of Pennsylvania, Clinical Research (OCR)
Philadelphia, Pennsylvania, 19104, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UCLA Hematology/Oncology
Los Angeles, California, 90095, United States
-
UZ Gent
Ghent, Oost-vlaanderen, 9000, Belgium